Oncolytics Biotech Inc. has been granted European Patent 1,309,672 entitled “Method of Producing Infectious Reovirus.” The claims relate to a method of producing infectious mammalian reovirus, which is suitable for clinical administration to mammals including humans.
“This patent is consistent with our strategy to continue to expand and strengthen our portfolio of intellectual property worldwide,” Dr. Matt Coffey, Chief Scientific Officer for Oncolytics said adding, “Along with our clinical trial and collaborative research programs in Europe, the United States and Canada, these patents are a key component of our development strategy for Reolysin.”
Oncolytics is a Calgary-based biotechnology company focused on the development of Reolysin, its proprietary formulation of the human reovirus, as a potential cancer therapeutic.